文献速递血栓与止血白血病

卡铂联合紫杉醇对比顺铂联合紫杉醇在理想减灭的III期卵巢癌患者中的III期试验:一项妇科肿瘤组研究

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study.
PubMed 文献 · J Clin Oncol · 2023-01-01

这项非劣效性III期随机试验纳入792例术后残留灶不超过1.0 cm的晚期卵巢癌患者,比较顺铂75 mg/m2加24小时紫杉醇135 mg/m2(第I组)与卡铂曲线下面积7.5加3小时紫杉醇175 mg/m2(第II组)。卡铂联合紫杉醇毒性更少、给药更方便且不劣于顺铂联合紫杉醇。

要点

  • 第I组胃肠道、肾脏、代谢毒性及4级白细胞减少显著更常见,第II组2级及以上血小板减少更常见。
  • 第I组中位无进展生存期19.4个月、总生存期48.7个月;第II组分别为20.7个月和57.4个月。
  • 卡铂联合紫杉醇组进展相对风险0.88(95%CI 0.75-1.03),死亡相对风险0.84(95%CI 0.70-1.02)。

核心结论

  • 在晚期卵巢癌患者中,卡铂联合紫杉醇方案毒性更少、给药更方便,且不劣于顺铂联合紫杉醇。

研究设计与样本

  • 随机非劣效性III期试验,纳入792例术后无大于1.0 cm残留肿块的晚期卵巢癌患者。
  • 第I组接受顺铂75 mg/m2加24小时输注紫杉醇135 mg/m2;第II组接受卡铂曲线下面积7.5静脉给药加3小时输注紫杉醇175 mg/m2。

主要发现

  • 第I组胃肠道、肾脏、代谢毒性及4级白细胞减少显著更常见;第II组2级及以上血小板减少更常见;两组神经毒性相似。
  • 第I组中位无进展生存期19.4个月、总生存期48.7个月;第II组分别为20.7个月和57.4个月。
  • 卡铂联合紫杉醇组进展相对风险0.88(95%CI 0.75-1.03),死亡相对风险0.84(95%CI 0.70-1.02)。

关键数值与推荐

  • 第I组顺铂75 mg/m2加24小时输注紫杉醇135 mg/m2;第II组卡铂曲线下面积7.5加3小时输注紫杉醇175 mg/m2。
  • 卡铂联合紫杉醇组进展相对风险0.88(95%CI 0.75-1.03),死亡相对风险0.84(95%CI 0.70-1.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in nonrandomized trials, carboplatin and paclitaxel was a less toxic and highly active combination regimen, there remained concern regarding its efficacy in patients with small-volume, resected, stage III disease. Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population.Patients and Methods: Patients with advanced ovarian cancer and no residual mass greater than 1.0 cm after surgery were randomly assigned to receive cisplatin 75 mg/m2 plus a 24-hour infusion of paclitaxel 135 mg/m2 (arm I), or carboplatin area under the curve 7.5 intravenously plus paclitaxel 175 mg/m2 over 3 hours (arm II).Results: Seven hundred ninety-two eligible patients were enrolled onto the study. Prognostic factors were similar in the two treatment groups. Gastrointestinal, renal, and metabolic toxicity, as well as grade 4 leukopenia, were significantly more frequent in arm I. Grade 2 or greater thrombocytopenia was more common in arm II. Neurologic toxicity was similar in both regimens. Median progression-free survival and overall survival were 19.4 and 48.7 months, respectively, for arm I compared with 20.7 and 57.4 months, respectively, for arm II. The relative risk (RR) of progression for the carboplatin plus paclitaxel group was 0.88 (95% confidence interval [CI], 0.75 to 1.03) and the RR of death was 0.84 (95% CI, 0.70 to 1.02).Conclusion: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ozols RF, Bundy BN, Greer BE, et al. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2023. PMID: 37643542. doi:10.1200/JCO.22.02766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。